Diabetic ketoacidosis
Disease8 papers2 findings
- Humans4
- In silico1
Associations
2SGLT2 inhibitors
upin humans1RR 2.06High certainty
1 study
SGLT2 inhibitors
upin humans1RR 2.06High certainty
SGLT2 inhibitors raise the risk of diabetic ketoacidosis in humans (RR 2.06, 95% CI 1.19-3.58).
Human trialchronic kidney disease
Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis · Frontiers in pharmacology · 31 Aug 2026
Sodium-glucose cotransporter 2 inhibitors
upin humans1Low certainty
1 study
Sodium-glucose cotransporter 2 inhibitors
upin humans1Low certainty
Sodium-glucose cotransporter 2 inhibitors raise the risk of diabetic ketoacidosis in humans (aHR 2.04, 95% CI 1.64-2.54).
Humansin patients with T2DM
Risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A nationwide cohort study · Sage open chronic disease · 19 Mar 2026
Trial sponsors
1 trialPhase 474 people
University of Colorado, Denver
1 trialPhase 461 people
1 trialPhase 439 people
Kinderkrankenhaus auf der Bult
1 trialPhase 12 people
Funding
National Institute of Diabetes and Digestive and Kidney DiseasesUS$1.5m1 grant since 2026